US Biosimilar Impact Set To Overtake Small-Molecule Generics

Biosimilars Set To Reduce Biologic Spending By Over $40bn Through 2026

 
• By Chloe Kent

The oncoming rush of biosimilars into the US pharmaceutical market is expected to exceed the impact of small molecule generic drugs for the first time, according to IQVIA research.

Hand holding a disintegrating one dollar bill
Loss of exclusivity is set to equal loss of profit for branded drug manufacturers. • Source: Shutterstock

More from Biosimilars

More from Products